Rhizen Pharmaceuticals SA Company

Rhizen is a clinical-stage biopharmaceutical company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders.
Industry: Genomic and Epigenominc Instabillity
Headquarters: Switzerland

Visit Website
info@rhizen.com
Register and Claim Ownership